Búsqueda Imágenes Maps Play YouTube Noticias Gmail Drive Más »
Iniciar sesión

Patentes

  1. Búsqueda avanzada de patentes
Número de publicaciónUS20070073354 A1
Tipo de publicaciónSolicitud
Número de solicitudUS 11/235,947
Fecha de publicación29 Mar 2007
Fecha de presentación26 Sep 2005
Fecha de prioridad26 Sep 2005
También publicado comoUS8798754, US20080154333, US20140046419, US20160144181, WO2007038200A1
Número de publicación11235947, 235947, US 2007/0073354 A1, US 2007/073354 A1, US 20070073354 A1, US 20070073354A1, US 2007073354 A1, US 2007073354A1, US-A1-20070073354, US-A1-2007073354, US2007/0073354A1, US2007/073354A1, US20070073354 A1, US20070073354A1, US2007073354 A1, US2007073354A1
InventoresMark Knudson, Adrianus Donders, Timothy Conrad
Cesionario originalKnudson Mark B, Donders Adrianus P, Conrad Timothy R
Exportar citaBiBTeX, EndNote, RefMan
Enlaces externos: USPTO, Cesión de USPTO, Espacenet
Neural blocking therapy
US 20070073354 A1
Resumen
A method and apparatus are disclosed for treating a variety of conditions include treating a disorder associated with neural activity near a region of a brain. In such condition, the method includes placing an electrode to create a field near said region, creating said field with parameters selected to at least partially block neural activity within said field. For treating a tissue sensation, the method includes identifying a target area of tissue to be treated and placing an electrode to create a field near the target area, and creating the field with parameters selected to at least partially block neural activity within the target area. For treating a condition associated with neural activity of a spinal cord, the method includes placing an electrode to create a field near a nerve associated with the spinal cord, and creating the field with parameters selected to at least partially block neural activity within the nerve.
Imágenes(7)
Previous page
Next page
Reclamaciones(10)
1. A method of treating a disorder associated with neural activity near a region of a brain, said method comprising:
placing an electrode to create a field near said region, creating said field with parameters selected to at least partially block neural activity within said field.
2. A method according to claim 1 comprising placing said electrode beneath a skull of said patient for said field to at least partially block neural activity within at least a portion of a cortex of said brain.
3. A method according to claim 1 comprising placing said electrode within a ventricle of said brain with said electrode positioned to block neural activity of a portion of said brain associated with hormone production.
4. An apparatus for treating a disorder associated with neural activity near a region of a brain, said apparatus comprising:
a electrode for creating a field near said region, said electrode adapted to be placed near said region
a controller for creating said field at said electrode with parameters selected to at least partially block neural activity within said field.
5. An apparatus according to claim 4 wherein said electrode is sized to be placed beneath a skull of said patient for said field to at least partially block neural activity within at least a portion of a cortex of said brain.
6. An apparatus according to claim 4 wherein said electrode is sized to be placed within a ventricle of said brain with said electrode positioned to block neural activity of a portion of said brain associated with hormone production.
7. A method of treating tissue sensation, said method comprising:
identifying a target area of tissue to be treated;
placing an electrode to create a field near said target area, creating said field with parameters selected to at least partially block neural activity within said target area.
8. An apparatus for treating tissue sensation, said method comprising:
an electrode for creating a field near said target area, said electrode adapted to be placed against a tissue surface;
a controller for creating said field at said electrode with parameters selected to at least partially block neural activity within said field.
9. A method of treating a condition associated with neural activity of a spinal cord, said method comprising:
placing an electrode to create a field near a nerve associated with said spinal cord, creating said field with parameters selected to at least partially block neural activity within said nerve.
10. An apparatus for treating a condition associated with neural activity of a spinal cord, said apparatus comprising:
an electrode to create a field near a nerve associated with said spinal cord, said electrode adapted to be positioned near said spinal cord;
a controller for creating said field with parameters selected to at least partially block neural activity within said nerve.
Descripción
    I. BACKGROUND OF THE INVENTION
  • [0001]
    1. Field of the Invention
  • [0002]
    This application pertains to method and apparatus for treating conditions associated with neuronal activity.
  • [0003]
    2. Description of the Prior Art
  • [0004]
    a. Neural Stimulation Treatments
  • [0005]
    The prior art contains numerous examples of treatments involving stimulation signals to nerves, muscles or organs for treating a wide variety of medical disorders.
  • [0006]
    U.S. Pat. Nos. 4,702,254 and 5,229,569 (both assigned to Cyberonics, Inc.) describe various central nervous system (CNS) treatments using electrical stimulation applied to the vagus nerve. For example, the '254 patent describes treatment of epilepsy. The '569 patent describes treatment of neuropsychiatric disorders. U.S. patent application Publ. No. 2003/0144709 (also assigned to Cyberonics, Inc.) describes treatment of pain through nerve stimulation.
  • [0007]
    U.S. patent application publication No. 2004/0243205 A1 to Keravel et al. published Dec. 2, 2004 and assigned to Medtronic, Inc., Minneapolis, Minn., USA (incorporated herein by reference) describes a paddle lead with multiple electrodes. The paddle is placed beneath the skull overlying a target area of the cerebral cortex. The electrodes record somaestheic-evoked potentials. The same electrodes may be used for a stimulation therapy.
  • [0008]
    Nerve stimulation and muscle stimulation have been suggested for treating gastro-intestinal (GI) disorders. Treatments of gastrointestinal diseases through nerve stimulation have been suggested. For example, U.S. Pat. No. 6,238,423 to Bardy dated May 29, 2001 describes a constipation treatment involving electrical stimulation of the muscles or related nerves of the gut. U.S. Pat. No. 6,571,127 to Ben-Haim et al. dated May 27, 2003 describes increasing motility by applying an electrical field to the GI tract. U.S. Pat. No. 5,540,730 to Terry, Jr. et al., dated Jul. 30, 1996 describes a motility treatment involving vagal stimulation to alter GI contractions in response to a sense condition indicative of need for treatment. U.S. Pat. No. 6,610,713 to Tracey dated Aug. 26, 2003 describes inhibiting release of a proinflammatory cytokine by treating a cell with a cholinergic agonist by stimulating efferent vagus nerve activity to inhibit the inflammatory cytokine cascade. U.S. Pat. No. 6,622,047 to Barret et al dated Sep. 16, 2003 described obesity treatment through vagal stimulation.
  • [0009]
    b. Neural Blocking
  • [0010]
    The fore-going treatments are stimulation for treatments. For those applying a signal to a nerve, the signal parameters (pulse width, frequency and amplitude) are selected to initiate neural action potentials to be propagated along the nerve to an organ (e.g., brain or stomach).
  • [0011]
    Not all electrical signals applied to nerves are stimulation signals. Certain parameters can result in a signal that inhibits the nerve or blocks the propagation of action potentials along the nerve.
  • [0012]
    Many different forms of nerve blocking are known. The present invention is an improvement upon a neural blocking to avoid antidromic influences during stimulation or to otherwise down-regulate nerve activity. Cryogenic nerve blocking of the vagus is described in Dapoigny et al., “Vagal influence on colonic motor activity in conscious nonhuman primates”, Am. J. Physiol., 262: G231-G236 (1992). Electrically induced nerve blocking is described in Van Den Honert, et al., “Generation of Unidirectionally Propagated Action Potentials in a Peripheral Nerve by Brief Stimuli”, Science, Vol. 206, pp. 1311-1312. An electrical nerve block is described in Solomonow, et al., “Control of Muscle Contractile Force through Indirect High-Frequency Stimulation”, Am. J. of Physical Medicine, Vol. 62, No. 2, pp. 71-82 (1983) and Petrofsky, et al., “Impact of Recruitment Order on Electrode Design for Neural Prosthetics of Skeletal Muscle”, Am. J. of Physical Medicine, Vol. 60, No. 5, pp. 243-253 (1981). A neural prosthesis with an electrical nerve block is also described in U.S. Patent Application Publication No. US 2002/0055779 A1 to Andrews published May 9, 2002. A cryogenic vagal block and resulting effect on gastric emptying are described in Paterson C A, et al., “Determinants of Occurrence and Volume of Transpyloric Flow During Gastric Emptying of Liquids in Dogs: Importance of Vagal Input”, Dig Dis Sci, (2000); 45:1509-1516.
  • [0013]
    A frequency of the blocking signal is greater than a 200 Hz threshold and, preferably, greater than 500 Hz. Solomonow, et al. “control of muscle contractile force through indirect high-frequency stimulation”, American Journal of Physical Medicine, Volume 62, No. 2, pages 71-82 (1983). Higher frequencies of as high as 5,000 Hz result in more consistent neural conduction block. Kilgore, et al., “Nerve Conduction Block Utilizing High-Frequency Alternating Current”, Medical and Biological Engineering and Computing, Vol. 24, pp. 394-406 (2004).
  • [0014]
    The nerve conduction block is applied with electrical signals selected to block the entire cross-section of the nerve (for example, both afferent, efferent, myelinated and non-myelinated fibers) at the site of applying the blocking signal (as opposed to selected sub-groups of nerve fibers or just afferent and not efferent or vice versa).
  • [0015]
    c. Use of Neural Blocking in Treatments
  • [0016]
    U.S. Pat. No. 5,188,104 to Wernicke et. al. Dated Feb. 23, 1993 describes sub-selection of fibers in a nerve by selecting a treatment frequency by which blocks certain nerve fiber types in the nerve while stimulating other nerve fiber types. Since certain fibers are stimulated while other fibers are blocked, there is no cross-section inhibition or blocking of the entire nerve and all of its nerve fiber types (for example, both afferent, efferent, myelinated and non-myelinated fibers).
  • [0017]
    U.S. Pat. No. 6,684,105 to Cohen et al. dated Jan. 27, 2004 (assigned to Biocontrol Medical Ltd.) teaches collision blocking in which a stimulation signal is applied to a nerves and an appropriately timed stimulus is applied to nerve to create neural impulses which collide with and thereby block propagation of the stimulation signal in a given direction. No therapy is achieved by the blocking. Such blocking avoids adverse side effects associated with permitting the stimulation signal propagating in an undesired direction to an organ not targeted for therapy.
  • [0018]
    U.S. patent application Publ. No. 2002/0055779 A1 published May 9, 2002 describes applying a high frequency block to a sciatic nerve to block undesired neural impulses which would otherwise contribute to spastic movement. With such spasm-inducing signals blocked, a therapy signal is applied to the muscle to stimulated desired muscle contractions. U.S. patent application Publ. No. 2005/0149148 A1 published Jul. 7, 2005 (assigned to Medtronic, Inc.) teaches using a blocking signal to avoid undesired side effect (i.e., pain) otherwise associated with a stimulation signal.
  • [0019]
    The use of a blocking signal as a therapy is described in various patent applications assigned to EnteroMedics, Inc. These applications pertain to use of a conduction block technology to a nerve for a treatment of a variety of disorders. These applications include the following (all filed Sep. 29, 2003): U.S. patent application Ser. No. 10/674,330 (published Sep. 2, 2004 as Publication No. US 2004/0172086 A1); U.S. patent application Ser. No. 10/675,818 (published Sep. 9, 2004 as US Patent Application Publication No. US 2004/0176812 A1) and U.S. patent application Ser. No. 10/674,324 (published Sep. 2, 2004 as US Patent Application Publication No. 2004/0172085 A1). The same assignee is assigned U.S. patent application Ser. Nos. 10/752,994 and 10/752,940 both filed Jan. 6, 2004 with respective publication dates of Aug. 26, 2004 and Sep. 2, 2004, Publication Nos. US 2004/0167583 A1 and 2004/0172088 A1.
  • [0020]
    The foregoing EnteroMedics patent applications describe, in a preferred embodiment, the application of neural conduction block therapy to a vagus nerve alone or in combination with a stimulation of the nerve. The conduction block therapy of the these patent applications includes application of an electrical signal with parameters selected to down-regulate vagal activity by creating conditions in which normal nerve propagation potentials are blocked at the application of the signal on both afferent and efferent nerves fibers of the vagus. Representative treatments described in these applications include the treatment of obesity, pancreatitis, pain, inflammation, functional GI disorders, irritable bowel syndrome and ileus.
  • [0021]
    d. Accommodation
  • [0022]
    Blockage of a nerve can result in nerve accommodation in which other nerve groups assume, in whole in part, the function of the blocked nerve. For example, sub-diaphragm blocking of the vagus nerve may be accommodated by the enteric nervous system. U.S. patent application Ser. No. 10/881,045 filed Jun. 30, 2004 (published Feb. 17, 2005 as Publication No. US 2005/0038484 A1) (assigned to EnteroMedics, Inc.) notes that a duty cycle of electrical impulses to the nerve to block neural conduction on the nerve can be adjusted between periods of blocking and no blocking in order to vary the amount of down regulation of the vagus nerve as well as preventing accommodation by the enteric nervous system.
  • [0023]
    e. Drug Treatments
  • [0024]
    Many symptoms of Parkinson's disease can be controlled with one of many currently available medications. These are divided into several classes of drugs including dopamine agonists, levodopa/decarboxylase inhibitors, anticholinergic agents, MAO-B inhibitors, and COMT (catechol-O-methyltransferase) inhibitors. These medications, whether used alone or in combination, not only replace the dopamine that has been lost in the brain, but also slow the rate of dopamine loss in the brain, and/or correct the imbalance between the levels of dopamine and acetylcholine in the brain. While none of these medications are a cure for Parkinson's disease, they can alleviate the symptoms of the disease and help its victims manage the disease.
  • [0025]
    One of the most effective and widely administered medications introduced in the 1970's to relieve symptoms of Parkinson's disease works as a dopamine replacement therapy. This drug is known as Sinemet (generic name of levodopa/carbidopa), its active ingredient being L-DOPA (L-3,4-dihydroxyphenylalanine). Levodopa is a generic name given to L-DOPA when it is produced as a drug. Unfortunately, dopamine cannot be administered directly to patients because it does not cross the blood-brain barrier. Hence, L-DOPA, which is the precursor form of dopamine, crosses the blood-brain barrier, and can be converted to dopamine in the brain, is the molecule of choice. However, due to the presence of aromatic amino acid decarboxylase (AADS) in the periphery of the brain, which will convert L-DOPA to dopamine before it crosses the blood brain barrier and prevent its passage to the brain, L-DOPA is administered with carbidopa, an AADS inhibitor. Carbidopa inhibits peripheral AADS action and thus reduces the amount of levodopa needed.
  • [0026]
    During the first few months the medication is administered, its benefits are maximal. However, patients taking Sinemet for a longer period are prone to the “wearing-off” effect, a tendency for the effectiveness of the drug to be lost with time. Hence, the dose of Sinemet will often have to be increased with time. Sometimes an “on-off effect,” where the symptoms become sporadic and unpredictable over a period of time, is also experienced. Moreover, as the dose of the medication is increased, some patients begin to experience side effects due an increase in brain dopamine levels. Some major side effects include anxiety, agitation, dyskinesia, vomiting, low blood pressure, hallucination and nausea (Nadeau 1997). The occurrence of side effects limits the further increase in Sinemet's dosage and at this point, treatment options become limited. Fortunately, carbidopa minimizes the incidence of vomiting and nausea. Furthermore, although levodopa/carbidopa treatment decreases bradykinesia and rigidity, it may not relieve tremor and balance.
  • [0027]
    Sinemet (unlike most medications that are absorbed into blood through the stomach) is absorbed from the small intestine. Anything that delays the movement of food from the stomach to the small intestine, such as foods rich in fat and protein, can reduce the amount of the drug absorbed. Moreover, levodopa has a very short plasma half-life. It disappears from the blood in 60 to 90 minutes. Because it is a type of amino acid called a large neutral amino acid (LNAA), it attaches itself during absorption to carrier molecules in the wall of the intestine and is then carried to the blood. Similarly, once in the blood, carrier molecules carry it across the blood-brain barrier. Amino acids such as isoleucine, leucine, valine, phenylalanine, tryptophan and tyrosine compete for the carrier with levodopa. Hence, a diet rich in protein can further compete with the Sinemet for entry into the brain. Thus, it is important to carefully evaluate one's diet when taking Sinemet.
  • [0028]
    Another medication that can be used alone or in combination with Sinemet is Eldepryl (generic name of selegeline). Selegeline is classified as a MAO-B inhibitor and is often administered in 5 mg capsules to help keep the Sinemet dose lower over time and therefore extend its administration period. In certain cases, it can delay the need for levodopa therapy by up to a year. By blocking the action of MAO-B, selegeline extends the capabilities of the dopamine in the synapse, delaying the breakdown of naturally occurring dopamine and dopamine administered as L-DOPA. Eldepryl thus slows dopamine loss in the synapse and makes it more likely that a dopamine will reach its corresponding receptor on the receiving nerve cell and transmit the correct message down the dopamine circuit. This is often referred to as dopamine conservation therapy.
  • [0029]
    During the Fourth International Congress of Movement Disorders held in Vienna during the summer of 1996, Eldepryl's benefits when administered in combination with Sinemet were affirmed. In fact, patients taking the drug combination were shown to experience motor fluctuations 1.8 years later on average than those taking only Sinemet. Another advantage of taking Eldepryl is that there is no specific dietary restriction associated with it if taken at the 5 mg dosage. Selegiline is an easy drug to take and has further been shown to protect the dopamine-producing neurons against the toxicity of MPTP. However, selegiline has its drawbacks. Patients have been known to experience side effects such as nausea, orthostatic hypotension and insomnia.
  • [0030]
    Dopamine agonists comprise another general category of drugs. Parlodel (generic name of bromocriptine), Permax (generic name of pergolide) and Symmetrel (generic name of amantadine) are examples. Parlodel and Permax mimic the action of dopamine by interacting with dopamine receptors in a form of dopamine substitution therapy. These two drugs enter the brain directly at dopamine receptor sites and prolong the duration of Sinemet's effects. An advantage of this approach is that it is less likely to cause dyskinesias (the occurrence of abnormal involuntary movements that results from the intake of high doses of L-DOPA). This is because the actual levels of dopamine do not increase in the brain, as is the case with Sinemet. Rather, a substitute form of dopamine is being used. However, these two drugs are less effective than L-DOPA in decreasing bradykinesia and rigidity and induce side effects such as paranoia, hallucinations, confusion, nausea and vomiting.
  • [0031]
    Symmetrel is an anti-viral drug used as a dopamine-releasing therapy in combination with Sinemet. It works by allowing the presynaptic neuron to more easily release dopamine into the synapse. More recently, it has been suggested that Symmetrel acts by binding to glutamate receptors in the subthalamic nucleus to help redress the imbalance in basal ganglia activity due to a deficiency in dopamine in a synergistic manner. Symmetrel is either used alone in the first stages of PD or in combination in the later stages. However, its effectiveness is known to wear off in a third to a half of the patients taking it. Furthermore, it induces side effects such as edema, blurred vision, depression, confusion and mottled skin.
  • [0032]
    Two new drugs, after having undergone extensive clinical trials, were made available in 1997. Requip (generic name of ropinirole) and Mirapex (generic name of pramipexole) are dopamine agonists. They are selective for the dopamine D3 receptor and are selectively targeted toward the basal ganglia. Both Requip and Mirapex can be used alone or with levodopa and both show fewer side effects than other drugs (Lozano et al. 1998).
  • [0033]
    Artane and Cogentine represent yet another class of drugs. They are classified as anti-cholinergic agents and are used to restore the imbalance between dopamine and acetylcholine levels in the brain. They work to reduce the activity of acetylcholine and hence reduce the tremor and stiffness of muscle that come about as a result of having more acetylcholine than dopamine in the brain.
  • [0034]
    Until the introduction of L-DOPA, anti-cholinergic agents were the main treatments for Parkinson's disease. Now Artane and Cogentine are usually administered in combination with other medications for their therapeutic effect. While effective, these drugs can also have side effects such as blurred vision, urinary retention, dry mouth, memory loss, and constipation. Hence, they are of limited use to the older population because they can cause serious neuropsychiatric side effects.
  • [0035]
    Tasmar (generic name of tolcapone) is a drug classified as a COMT inhibitor. COMT is a peripheral enzyme that reduces levodopa to a less active form. Tasmar, which became available in February 1998, has a different action than that of the dopamine agonists, in that when COMT activity is blocked, dopamine remains in the brain for a longer period of time. Hence, when administered with levodopa, COMT inhibitors prolong the duration time of Sinem.
  • II. SUMMARY OF THE INVENTION
  • [0036]
    A method and apparatus are disclosed for treating a variety of conditions. These include treating a disorder associated with neural activity near a region of a brain. In such condition, the method includes placing an electrode to create a field near said region, creating said field with parameters selected to at least partially block neural activity within said field. For treating a tissue sensation, the method includes identifying a target area of tissue to be treated and placing an electrode to create a field near the target area, and creating the field with parameters selected to at least partially block neural activity within the target area. For treating a condition associated with neural activity of a spinal cord, the method includes placing an electrode to create a field near a nerve associated with the spinal cord, and creating the field with parameters selected to at least partially block neural activity within the nerve.
  • III. BRIEF DESCRIPTION OF THE DRAWINGS
  • [0037]
    FIG. 1 is a top plan view of a patient's head and showing an electrode array according to the present invention in phantom lines positioned beneath a skull of the patient;
  • [0038]
    FIG. 2 is a side elevation view of a patient with an electrode patch beneath the skull of the patient and shown in phantom lines with a lead to a control unit positioned in the patient's neck;
  • [0039]
    FIG. 3 is a view of a brain of a patient shown in lateral cross-section and with a patch according to the present invention residing between the skull and the surface of the patient's brain over a cortex of the patient's brain;
  • [0040]
    FIG. 4 is a plan view of an electrode patch according to the present invention;
  • [0041]
    FIG. 5 is an anterior-posterior, cross-sectional view of a patient's brain showing an alternative embodiment of electrodes placed on a catheter advanced through the ventricle of the brain;
  • [0042]
    FIG. 6 is a plan view of inside surfaces of an upper arm and forearm and hand of a patient with an alternative embodiment of the present invention positioned surrounding a target area for needle insertion;
  • [0043]
    FIG. 7 is a side elevation view of a section of the electrode patch of FIG. 6;
  • [0044]
    FIG. 8 is a graphical presentation of representative waveforms according to the present invention for energizing the electrodes of FIG. 6;
  • [0045]
    FIG. 9 is an illustration of a patient's finger showing electrodes on the opposite side of a target area at the fingertip of the patient;
  • [0046]
    FIG. 10 illustrates electrodes on mucosal tissue on opposite sides of a tooth to apply a blocking signal;
  • [0047]
    FIG. 11 is a cross-section view of a vertebral body and showing anatomical components and a blocking signal electrode on a dorsal root;
  • [0048]
    FIG. 12 is a schematic longitudinal, side-sectional showing of a segment of a spine with a catheter placement of an electrode on a dorsal root; and
  • [0049]
    FIG. 13 is an anterior-posterior schematic representation of a segment of a spine with blocking signal electrodes shown in two positions.
  • IV. DESCRIPTION OF A PREFERRED EMBODIMENT
  • [0050]
    With reference now to the various drawing figures in which identical elements are identically numbered, preferred embodiments of the present invention will now be described.
  • [0051]
    A. Central Nervous System (CNS) Treatment
  • [0052]
    Certain disorders (e.g., epilepsy and Parkinson's disease and other motor disorders of CNS origin) are believed to be associated with hormonal imbalance.
  • [0053]
    Movement disorders associated with cerebral activity are not fully understood. However, certain disorders such as epilepsy and Parkinson's disease are believed to be associated with an imbalance of hormonal production deep within the brain.
  • [0054]
    For example, certain regions deep within the brain produce the hormones glutamate and dopamine. Glutamate enhances conductivity of the nerve cells of the brain while dopamine reduces or inhibits such conductivity.
  • [0055]
    With reference to FIG. 3, dopamine is produced within a region of the brain known as the substantia nigra SN. Glutamate is produced in the thalamus region of the brain, which includes the ventral anterior nucleus VAN, the ventral lateral nucleus VLN and the centromedian nucleus CN. The produced hormones are projected throughout the brain including to the cortex which is the outer region of the brain near the back of the head and illustrated generally by C in FIG. 3.
  • [0056]
    The projection to the cortex C of the glutamate is believed to flow from production of glutamate in the ventral anterior nucleus VAN. Such projection is illustrated by the arrow AG in FIG. 3. The projection of dopamine to the cortex is believed to flow from the substantia nigra SN with such projection illustrated in FIG. 3 by the arrow AD.
  • [0057]
    The presence of dopamine and glutamate in the cortex C alter the conductivity of the nerve cells in the cortex C. Certain motor disorders such as epilepsy and Parkinson's disease, are believed to be associated with a deficiency of dopamine production which results in excessively enhanced conductivity in the cortex since the enhancing hormone, glutatmate, is disproportionately high relative to the inhibiting conductivity hormone, dopamine.
  • [0058]
    The present invention compensates for hormonal imbalance resulting in excessive conductivity by altering the conductivity at the cortex. The conductivity of the cortex and electrical activity of the cortex controls motor functions of the patient.
  • [0059]
    The present invention is a patch electrode 10, which is placed beneath the skull of the patient between the skull S and the cortex C (FIG. 3). The patch electrode 10 includes a flexible flat substrate 12 of electrically insulating material such as silicone or the like. Exposed on one surface of the substrate 12 are a plurality of electrically conductive electrodes, which, in a preferred embodiment, are arranged in an array of rows and columns.
  • [0060]
    In the specific examples shown in FIGS. 3 and 4, there is a first row containing electrodes E1, 1 through E1,5. The second row contains five electrodes E2, 1 through E2, 5. The third row contains electrodes E3, 1 through E3, 5. The fourth row contains electrodes E4, 1 through E4, 5. The fifth row contains electrodes E5, 1 through E5, 5. The patch 10 is dimensioned for the array of electrodes to cover at least a portion of the cortex C of the brain and with the electrodes of the array in electrically conductive contact with the cortex C.
  • [0061]
    As illustrated in FIGS. 1 and 2, the patch electrode 10 is placed over the cortex beneath the skull on either the left (FIG. 1) or right (FIG. 2) of the brain. In FIG. 1, the top of a patient's head H is shown with an anterior-posterior axis A-P separating the patients' left L and right R sides.
  • [0062]
    As shown in FIG. 2, a lead 16 from the patch electrode 10 may be tunneled between the skull S and the brain B through the base of the skull and terminated at a control unit 20 which may be positioned within the neck or implanted lower in the patient such in the shoulder or clavicle area or the like. The lead 16 is a highly flexible conductor containing individual conductors for each of the electrodes of the array of the patch 10 and encased within a highly flexible insulative material such as silicone or the like.
  • [0063]
    The controller 20 may be an implantable pulse generator (with separate power source such as either rechargeable batteries or replaceable batteries) or may be a control unit, which receives power and pacing signals from an external control unit, which transmits via radio frequency transmission to the controller 20. For the purpose of this description, the controller 20 will be treated as a completely contained controller having both logic circuits and power source. It will be appreciated that such controllers may be also programmable from external programmable sources as is known in the art for controlling implantable pulse generators for cardiac pacing.
  • [0064]
    The circuitry of the controller 20 permits energizing selective ones of the electrodes of the array in bi-polar electrode pairs. For example, electrodes E5, 1 and E4, 2 may be energized with oppositely polarized waveforms to create an electrical field F1 between the electrodes E5, 1 and E4, 2. By oppositely charged waveforms it will be appreciated that electrode E5, 1 is positively charged while E4, 2 is negatively charged and E5, 1 is negatively charged while E4, 2 is positively charged. When the electrode pair E5, 1 and E4, 2 is charged to create the field F1, all remaining electrodes may be inactive or otherwise charged to create more complex electrical fields.
  • [0065]
    FIG. 4 illustrates a field F2 created between electrode pairs E2, 2 and E2, 4 and a field F3 between electrode pairs E1, 1 and E5, 5. While multiple electrode pairs may be simultaneously charged, the controller 20 may also control the electrodes so that the waveform applied to the electrodes has a built-in delay period such that a particular electrode pair is not charged and in its delay period, while other electrode pairs are being charged. Accordingly, multiple pairs of electrodes may be charged with the waveforms of the electrode pairs being nested so that only one electrode pair is charged at any one unit of time. An example of a nested set of waveforms will be later described.
  • [0066]
    Preferably, the waveform selected is a blocking waveform to block neuronal activity. For example, the frequency of the field will have a pulse width selected for the generated field to have a frequency in excess of a 200 Hz threshold as described by Solomonow (article previously described) and, more preferably, 5,000 Hz or higher as described in Kilgore (article previously described). A 5,000 Hz signal will have a pulse width of about 100 microseconds. A representative amplitude for such signals would be 0.2 to 8 mA.
  • [0067]
    The effect of applying a blocking signal to the cortex reduces the excessive electrical activity otherwise associated with a dopamine deficiency. Further, the therapy of the present invention is localized to the area of interest, namely, the cortex region of the brain, which contributes to the symptoms of motor disorders. Other regions of the brain are not affected and no systemic drug is given to the patient.
  • [0068]
    The programming of the controller 20 may permit altering the selected individual electrodes, which form an electrode pair. Any two electrodes on the patch 10 may be formed to a pair to create a field between the pair. As a result, at time of placement of the patch 10, the patch need not be precisely placed to achieve an interruption or inhibition of electrical activity in the cortex. Instead, different permutations of coupled electrode pairs may be tested to observe patient response post-surgery.
  • [0069]
    The forgoing has illustrated use of the blocking signals to compensate and down regulate cortex electrical conductivity in response to dopamine deficiency. FIG. 5 illustrates use of stimulation signals to result in localized production of dopamine. In FIG. 5, a catheter 30 is advanced into the ventricles of the brain with a distal tip 32 positioned in the region of the hypothalamus of the brain. The tip 32 includes an electrode pair EA and EB, which form a bi-polar electrode pair. The electrodes are individually electrically connected to a controller (not shown but such as controller 20 previously described) for creating a desired waveform (as will be described). The controller provides the electrodes with either a stimulation signal (for example 20 Hz or any other signal less than 200 Hz) or a blocking signal as previously described. Energizing the electrodes with a stimulation signal can be tested on a particular patient to note any increase in dopamine production and result in cortex activity. Similarly, a blocking signal can be applied to note any reduction in glutamate production.
  • [0070]
    B. Peripheral Nervous System Treatment
  • [0071]
    The use of blocking signals as described may be used to alleviate pain on the surface of the skin for a wide variety of applications. For example, FIGS. 6 and 7 illustrate a patch 110 which may be placed on the skin surrounding a target area T associated with pain.
  • [0072]
    In the particular illustration of FIG. 6, a patient's required to give blood samples frequently require a needle injection into the interior surface of the arm to insert a needle into a vein between the upper arm UA and the forearm FA. The health care technician's identification of the particular vein for puncture is identified and circled by a target area T in phantom lines in FIG. 6.
  • [0073]
    A patch 110 is a ring-shaped substrate 112 sized to surround the target area T but otherwise permits access to the target area T by a needle (not shown) for drawing blood or the like. An undersurface of the substrate 112 contains diametrically opposite electrode pairs E1, A, E1, B and E2, A, E2, B and E3, A, E3, B. The electrodes are individually electrically connected to a controller (not shown but such as controller 20 previously described) for creating a desired waveform (as will be described). Between the electrodes adhesive layers 114 are provided to secure the patch 110 in place on the patient's skin surrounding the target area T.
  • [0074]
    The individual electrode pairs are bi-polar electrode pairs, which may be provided with a blocking signal as previously described. For example, the electrode pair E1, A, E1, B may be provided with a first waveform W1 illustrated in FIG. 8. The electrode pair E2, A, E2, B may be provided with a second waveform W2 and electrode pairs E3, A, E3, B may be provided with a third waveform W3 in FIG. 8.
  • [0075]
    Each of the waveforms W1, W2 and W3 are identical differing only in their timing. The waveforms are preferably blocking waveforms having a frequency in excess of a few hundred Hz threshold and more preferably having a frequency of about 5,000 Hz. With such a frequency, the waveforms have a pulse duration D of 100 microseconds. Preferably, each cycle of the waveform has a delayed period DP between the pulses with the duration of the delay period DP equal to two complete cycles (i.e., four pulse durations D or 400 microseconds). The amplitude of the pulse A may be any suitable amplitude to encourage current flow between the electrode pairs. To drive current across the skin, higher energy levels are anticipated (e.g., voltages up to about 35 volts and currents up to 25 mA.
  • [0076]
    The waveforms are offset relative to one another so that when any one electrode pair is receiving a pulse, the other electrode pairs are inactive resulting in three nested waveforms as illustrated in FIG. 8. Such waveforms create an electrical field between the diametrically opposed electrodes of a particular pair with the field passing through the target area T to block neuronal activity within the target area. Accordingly, when the electrodes are energized with the blocking signals as described, pain is not sensed during needle insertion into the target area T.
  • [0077]
    It will be appreciated in FIG. 6 the apparatus 110 will further include electrical leads to a control unit both of which are not shown for ease of illustration.
  • [0078]
    FIG. 9 illustrates an alternative application where two electrodes E1 E2 are placed on opposite sides of a target area T near the fingertip of a patient's finger F. For ease of illustration, a substrate for the electrodes is not shown. The electrodes are individually electrically connected to a controller (not shown but such as controller 20 previously described) for creating a desired waveform. The application of FIG. 9 is particularly useful for numbing a fingertip prior to lancing the fingertip for a blood sample for periodic blood sugar tests by diabetic patients.
  • [0079]
    FIG. 10 illustrates a still further embodiment where electrodes E1 and E2 are placed on opposite sides of the gum of the patient overlying mucosal tissue MT on opposite sides of a tooth T. Application of a blocking signal as previously described to the electrodes creates a blocking field to block nerves within the mucosal tissue for treatment of pain associated with gums or teeth or to precondition the tissue prior to injection of local anesthetics such as Novocain or Lydacain or other procedure occurring at the tissue.
  • [0080]
    C. Spinal Cord Treatment
  • [0081]
    FIGS. 11-13 illustrate application of the present invention to the spinal cord. By way of anatomical background, FIG. 11 shows, in cross section, a spinal cord SC position between an anterior vertebral body AVB and a posterior vertebral body PVB. The patient's anterior-posterior axis A-P is shown separating the patient's right R and left L sides.
  • [0082]
    The spinal cord SC is shown enclosed within a dural layer D with opposing surfaces of the spinal cord SC and the dural D defining a subanachroid space SAS. Extending laterally away from the spinal cord are left and right ventral roots LVR, RVR and right and left dorsal roots RDR, LDR. Also illustrated is a ganglion G. The spinal cord SC is illustrated as having identifiable areas of afferent and efferent fibers including ascending pathways AP areas and descending pathways DP areas.
  • [0083]
    According to the present invention, an electrode E is advanced either through open surgical or minimally invasive techniques into the subanachroid space SAS and positioned on a root such as the right dorsal root RDR. Application of a blocking signal to the electrode E blocks signals such as pain signals from the dorsal root the spinal cord SC. While a single monopolar electrode E is shown in FIG. 11, it will be appreciated that multiple electrodes including bipolar electrodes may be placed on the roots. For spinal treatments, such blocking signal may be as previously described and, preferably, has a frequency in excess of 3,000 Hz and more preferably about 5,000 Hz or more.
  • [0084]
    FIG. 12 is shown in vertical cross section with multiple vertebral bodies and with a spinal cord extending between the vertebral bodies. For ease of schematic illustration, the dorsal roots are shown extending between the anterior bodies. It will be appreciated that such roots extend laterally from the spinal cord.
  • [0085]
    A catheter C is shown in phantom lines for advancing an electrode to a dorsal root for placing the electrode on the dorsal root. The electrode lead extends from the electrode through implantable or external pulse generator as previously described.
  • [0086]
    FIG. 13 illustrates an electrode E (the upper electrode E in the view of FIG. 13) placed on a dorsal root either surgically or through catheter delivery as previously described. Further, FIG. 13 shows an electrode E (the lower electrode E in the view of FIG. 13) placed overlying the spinal cord over a target area AP, In the example of FIG. 13, the target area AP is an identified area of ascending pathways for application of a blocking signal to the ascending pathways for blocking transmission of neural signals to the brain. The electrode is supported on a sling S which is mounted on the left and right dorsal roots. It will be appreciated that the electrode so supported can be positioned over any area of the spinal cord to affect any desired area of ascending pathways or descending pathways. The electrodes are individually electrically connected to a controller (not shown but such as controller 20 previously described) for creating a desired waveform.
  • [0087]
    With the foregoing detailed description of the present invention, it has been shown how the objects of the invention have been attained in a preferred manner. Modifications and equivalents of disclosed concepts such as those which might readily occur to one skilled in the art, are intended to be included in the scope of the claims which are appended hereto.
Citas de patentes
Patente citada Fecha de presentación Fecha de publicación Solicitante Título
US1597601 *10 Jul 192524 Ago 1926Kilbride John JMultiple-valve grinder
US3646940 *15 Jul 19697 Mar 1972Univ MinnesotaImplantable electronic stimulator electrode and method
US3817254 *8 May 197218 Jun 1974Medtronic IncTranscutaneous stimulator and stimulation method
US3822708 *7 Dic 19729 Jul 1974Clinical Technology CorpElectrical spinal cord stimulating device and method for management of pain
US3893463 *7 Dic 19738 Jul 1975Medtronic IncDual channel stimulator
US4055190 *19 Dic 197425 Oct 1977Michio TanyElectrical therapeutic apparatus
US4315503 *5 Dic 197916 Feb 1982Electro-Biology, Inc.Modification of the growth, repair and maintenance behavior of living tissues and cells by a specific and selective change in electrical environment
US4459989 *30 Jun 198117 Jul 1984Neuromed, Inc.Non-invasive multiprogrammable tissue stimulator and methods for use
US4535777 *28 Sep 198420 Ago 1985Physio Technology, Inc.Method of providing electrical stimulation of tissue
US4702254 *30 Dic 198527 Oct 1987Jacob ZabaraNeurocybernetic prosthesis
US5121754 *21 Ago 199016 Jun 1992Medtronic, Inc.Lateral displacement percutaneously inserted epidural lead
US5188104 *1 Feb 199123 Feb 1993Cyberonics, Inc.Treatment of eating disorders by nerve stimulation
US5229569 *30 May 199120 Jul 1993Hitachi, Ltd.Laser machining apparatus and method of the same
US5417719 *25 Ago 199323 May 1995Medtronic, Inc.Method of using a spinal cord stimulation lead
US5501703 *24 Ene 199426 Mar 1996Medtronic, Inc.Multichannel apparatus for epidural spinal cord stimulator
US5540730 *6 Jun 199530 Jul 1996Cyberonics, Inc.Treatment of motility disorders by nerve stimulation
US5562717 *21 May 19938 Oct 1996Axelgaard Manufacturing Company, Ltd.Electrical stimulation for treatment of incontinence and other neuromuscular disorders
US5643330 *12 Feb 19961 Jul 1997Medtronic, Inc.Multichannel apparatus for epidural spinal cord stimulation
US5716377 *25 Abr 199610 Feb 1998Medtronic, Inc.Method of treating movement disorders by brain stimulation
US5733322 *23 May 199531 Mar 1998Medtronic, Inc.Positive fixation percutaneous epidural neurostimulation lead
US5792187 *5 Oct 199511 Ago 1998Angeion CorporationNeuro-stimulation to control pain during cardioversion defibrillation
US5895416 *12 Mar 199720 Abr 1999Medtronic, Inc.Method and apparatus for controlling and steering an electric field
US5925070 *10 Mar 199720 Jul 1999Medtronic, Inc.Techniques for adjusting the locus of excitation of electrically excitable tissue
US5948007 *30 Abr 19977 Sep 1999Medtronic, Inc.Dual channel implantation neurostimulation techniques
US6027456 *10 Jul 199822 Feb 2000Advanced Neuromodulation Systems, Inc.Apparatus and method for positioning spinal cord stimulation leads
US6104957 *21 Ago 199815 Ago 2000Alo; Kenneth M.Epidural nerve root stimulation with lead placement method
US6238423 *30 Sep 199929 May 2001Medtronic, Inc.Apparatus and method for treating chronic constipation
US6246912 *19 Jul 199912 Jun 2001Sherwood Services AgModulated high frequency tissue modification
US6341236 *30 Abr 199922 Ene 2002Ivan OsorioVagal nerve stimulation techniques for treatment of epileptic seizures
US6356786 *20 Ene 200012 Mar 2002Electrocore Techniques, LlcMethod of treating palmar hyperhydrosis by electrical stimulation of the sympathetic nervous chain
US6381496 *25 Sep 200030 Abr 2002Advanced Bionics CorporationParameter context switching for an implanted device
US6421566 *12 Jun 200016 Jul 2002Medtronic, Inc.Selective dorsal column stimulation in SCS, using conditioning pulses
US6438423 *25 Ene 200020 Ago 2002Electrocore Technique, LlcMethod of treating complex regional pain syndromes by electrical stimulation of the sympathetic nerve chain
US6516227 *26 Jul 20004 Feb 2003Advanced Bionics CorporationRechargeable spinal cord stimulator system
US6571127 *11 Ene 200027 May 2003Impulse Dynamics N.V.Method of increasing the motility of a GI tract
US6587727 *9 Nov 20011 Jul 2003Ivan OsorioVagal nerve stimulation techniques for treatment of epileptic seizures
US6600954 *4 Abr 200129 Jul 2003Biocontrol Medical Bcm Ltd.Method and apparatus for selective control of nerve fibers
US6609030 *24 Feb 200019 Ago 2003Electrocore Techniques, LlcMethod of treating psychiatric diseases by neuromodulation within the dorsomedial thalamus
US6609031 *7 Jun 199619 Ago 2003Advanced Neuromodulation Systems, Inc.Multiprogrammable tissue stimulator and method
US6610713 *15 May 200126 Ago 2003North Shore - Long Island Jewish Research InstituteInhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6622047 *28 Jul 200116 Sep 2003Cyberonics, Inc.Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation
US6675046 *7 May 20026 Ene 2004Medtronic, Inc.Selective dorsal column stimulation in SCS, using conditioning pulses
US6684105 *31 Ago 200127 Ene 2004Biocontrol Medical, Ltd.Treatment of disorders by unidirectional nerve stimulation
US6754539 *10 Ago 200022 Jun 2004Advanced Neuromodulation Systems, Inc.Spinal cord stimulation lead with an anode guard
US6761715 *5 Feb 200213 Jul 2004Ronald J. CarrollMethod and device for neurocryo analgesia and anesthesia
US6895280 *27 Nov 200217 May 2005Advanced Bionics CorporationRechargeable spinal cord stimulator system
US6928280 *17 Abr 20009 Ago 2005Telephia, Inc.Method and system for measuring data quality of service in a wireless network using multiple remote units and a back end processor
US6928320 *17 May 20019 Ago 2005Medtronic, Inc.Apparatus for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated
US7047079 *25 Jul 200316 May 2006Advanced Neuromodulation Systems, Inc.Method and system for energy conservation in implantable stimulation devices
US7117034 *24 Jun 20043 Oct 2006Healthonics, Inc.Apparatus and method for bioelectric stimulation, healing acceleration, pain relief, or pathogen devitalization
US7177690 *31 Ene 200313 Feb 2007Advanced Bionics CorporationImplantable system having rechargeable battery indicator
US7177691 *18 Abr 200313 Feb 2007Advanced Bionics CorporationImplantable pulse generators using rechargeable zero-volt technology lithium-ion batteries
US7212865 *25 May 20041 May 2007Philip CoryNerve stimulator and method
US7260436 *16 Oct 200221 Ago 2007Case Western Reserve UniversityImplantable networked neural system
US7263402 *5 Ago 200228 Ago 2007Advanced Bionics CorporationSystem and method of rapid, comfortable parameter switching in spinal cord stimulation
US7333857 *16 Jul 200419 Feb 2008Arcl, Inc.Treatment of pain
US7337005 *7 Sep 200526 Feb 2008Spinal Modulations, Inc.Methods for stimulating a nerve root ganglion
US7337006 *7 Sep 200526 Feb 2008Spinal Modulation, Inc.Methods and systems for modulating neural tissue
US7389145 *20 Feb 200217 Jun 2008Case Western Reserve UniversitySystems and methods for reversibly blocking nerve activity
US7502651 *7 Sep 200510 Mar 2009Spinal Modulation, Inc.Methods for stimulating a dorsal root ganglion
US7502652 *23 Ene 200610 Mar 2009Rehabtronics, Inc.Method of routing electrical current to bodily tissues via implanted passive conductors
US20020055779 *5 Mar 19979 May 2002Brian J. AndrewsNeural prosthesis
US20020116030 *23 Oct 200122 Ago 2002Rezai Ali R.Electrical stimulation of the sympathetic nerve chain
US20030144709 *25 Ene 200231 Jul 2003Cyberonics, Inc.Nerve stimulation as a treatment for pain
US20040044379 *20 Mar 20034 Mar 2004Medtronic, Inc.Selective dorsal column stimulation in SCS, using conditioning pulses
US20040065394 *2 May 20038 Abr 2004Sungwoo Hitech Co., Ltd.Warm hydro-forming method and apparatus for aluminum alloys
US20040073273 *6 Oct 200315 Abr 2004Gluckman Bruce J.Adaptive electric field modulation of neural systems
US20040093093 *13 Ene 200313 May 2004The Governors Of The University Of AlbertaNeural prosthesis
US20040127953 *20 Feb 20021 Jul 2004Kilgore Kevin L.Systems and methods for reversibly blocking nerve activity
US20040167584 *22 Ene 200426 Ago 2004Carroll William J.Spinal cord stimulation with interferential current
US20050038490 *23 Sep 200417 Feb 2005Biocontrol Medical Ltd.Electrode assembly for nerve control
US20050107841 *10 Dic 200419 May 2005Meadows Paul M.Rechargeable spinal cord stimulator system
US20050119713 *30 Dic 20042 Jun 2005Whitehurst Todd K.Methods for implanting a spinal cord stimulator
US20050240242 *12 Jul 200427 Oct 2005Dilorenzo Daniel JClosed-loop feedback-driven neuromodulation
US20060041285 *3 Ago 200523 Feb 2006Johnson Robert GPortable unit for treating chronic pain
US20060052826 *7 Sep 20059 Mar 2006Kim Daniel HPulse generator for high impedance electrodes
US20060052836 *7 Sep 20059 Mar 2006Kim Daniel HNeurostimulation system
US20060116742 *20 Oct 20051 Jun 2006Dirk De RidderSpinal cord stimulation to treat auditory dysfunction
US20070021801 *14 Mar 200625 Ene 2007Medtronic, Inc.Regional therapies for treatment of pain
US20070021802 *14 Mar 200625 Ene 2007Medtronic, Inc.Regional therapies for treatment of pain
US20070032827 *8 Ago 20068 Feb 2007Katims Jefferson JMethod and apparatus for producing therapeutic and diagnostic stimulation
US20070039625 *14 Mar 200622 Feb 2007Medtronic, Inc.Regional therapies for treatment of pain
US20070060954 *27 Feb 200615 Mar 2007Tracy CameronMethod of using spinal cord stimulation to treat neurological disorders or conditions
US20070142863 *15 Dic 200521 Jun 2007Kerry BradleyApparatus and methods for stimulating tissue
US20070150034 *9 Jun 200628 Jun 2007Medtronic, Inc.Implantable medical lead
US20070213771 *7 Mar 200613 Sep 2007Spinner Robert JRegional anesthetic
US20070239226 *13 Jun 200711 Oct 2007Advanced Bionics CorporationGradual Recruitment of Muscle/Neural Excitable Tissue Using High-Rate Electrical Stimulation Parameters
US20070244522 *13 Jun 200718 Oct 2007Advanced Bionics CorporationGradual Recruitment of Muscle/Neural Excitable Tissue Using High-Rate Electrical Stimulation Parameters
US20080015667 *13 Jul 200617 Ene 2008Yossi GrossPeltier unidirectional and selective nerve stimulation
US20080058878 *31 Oct 20076 Mar 2008Medtronic, Inc.Therapeutic method with pain relief
US20080058888 *31 Oct 20076 Mar 2008King Gary WMethod For Blocking Activation Of Tissue Or Conduction Of Action Potentials While Other Tissue Is Being Therapeutically Activated
US20080109045 *31 Oct 20078 May 2008Yossi GrossSelective nerve fiber stimulation for treating conditions
US20080234791 *17 Ene 200825 Sep 2008Jeffrey Edward ArleSpinal cord implant systems and methods
US20090204173 *4 Nov 200813 Ago 2009Zi-Ping FangMulti-Frequency Neural Treatments and Associated Systems and Methods
US20100191307 *29 Ene 200929 Jul 2010Zi-Ping FangSystems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US20100274312 *22 Abr 201028 Oct 2010Konstantinos AlatarisSpinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods
US20100274314 *22 Abr 201028 Oct 2010Konstantinos AlatarisSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20100274315 *22 Abr 201028 Oct 2010Konstantinos AlatarisSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods, including practitioner processes
US20100274326 *22 Abr 201028 Oct 2010Yougandh ChitreSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods, including implantable patient leads
Citada por
Patente citante Fecha de presentación Fecha de publicación Solicitante Título
US817067526 Sep 20111 May 2012Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US820902126 Sep 201126 Jun 2012Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US825505729 Ene 200928 Ago 2012Nevro CorporationSystems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US835579213 Abr 201215 Ene 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US8359102 *13 Abr 201222 Ene 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US835910313 Abr 201222 Ene 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US839655916 Feb 201212 Mar 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US842314726 Sep 201116 Abr 2013Nevro CorporationDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified controllers
US842874813 Abr 201223 Abr 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US850990513 Abr 201213 Ago 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US85099069 Jul 201213 Ago 2013Nevro CorporationSystems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US855432614 Mar 20138 Oct 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US861201820 May 200817 Dic 2013Ivor Stephen GillbeArray stimulator
US864987430 Nov 201111 Feb 2014Nevro CorporationExtended pain relief via high frequency spinal cord modulation, and associated systems and methods
US867632222 Ene 200918 Mar 2014Boston Scientific Neuromodulation CorporationMethods and systems of treating pancreatitis pain
US867633114 Mar 201318 Mar 2014Nevro CorporationDevices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection
US869410822 Abr 20108 Abr 2014Nevro CorporationDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified controllers
US869410921 Dic 20128 Abr 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US8712533 *22 Abr 201029 Abr 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US8718778 *18 Sep 20086 May 2014Research Foundation Of The City University Of New YorkApparatus and method for neurocranial electrostimulation
US871878127 Dic 20126 May 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US8718782 *14 Mar 20136 May 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US87684724 Dic 20121 Jul 2014Nevro CorporationMulti-frequency neural treatments and associated systems and methods
US87749264 Dic 20128 Jul 2014Nevro CorporationMulti-frequency neural treatments and associated systems and methods
US8792988 *25 Sep 201329 Jul 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US879875410 Mar 20085 Ago 2014Venturi Group, LlcNeural blocking therapy
US883824822 Abr 201016 Sep 2014Nevro CorporationDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified program selection
US88494105 Abr 201330 Sep 2014Nevro CorporationSystems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US8862239 *25 Sep 201314 Oct 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US886819224 Ene 201421 Oct 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US887421714 Mar 201328 Oct 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US887422114 Mar 201328 Oct 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US887422224 Ene 201428 Oct 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US888017724 Ene 20144 Nov 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US8886326 *24 Ene 201411 Nov 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US8886327 *24 Ene 201411 Nov 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US88863286 Mar 201411 Nov 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US8892209 *25 Sep 201318 Nov 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US891411222 Ene 200916 Dic 2014Boston Scienctific Neuromodulation CorporationMethods and systems of treating pancreatitis pain caused by sphincter of Oddi dysfunction
US8989865 *14 Sep 201224 Mar 2015Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US900246029 Ene 20147 Abr 2015Nevro CorporationDevices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection
US918029824 Ene 201410 Nov 2015Nevro Corp.Extended pain relief via high frequency spinal cord modulation, and associated systems and methods
US92482938 Sep 20142 Feb 2016Nevro CorporationDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified program selection
US9278215 *14 Mar 20138 Mar 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US9283387 *14 Mar 201315 Mar 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US9283388 *14 Mar 201315 Mar 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US928961027 Ago 201222 Mar 2016Boston Scientific Neuromodulation CorporationFractionalized stimulation pulses in an implantable stimulator device
US9295839 *14 Mar 201329 Mar 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US9327121 *7 Sep 20123 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US932712524 Abr 20143 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US932712610 Oct 20143 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US9327127 *27 Oct 20143 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US933335730 Sep 201410 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US933335830 Sep 201410 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US933335930 Sep 201410 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US933336010 Oct 201410 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US938732723 Oct 201412 Jul 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US939342311 Jul 201419 Jul 2016Boston Scientific Neuromodulation CorporationFractionalized stimulation pulses in an implantable stimulator device
US940301310 Sep 20142 Ago 2016Nevro CorporationSystems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US94090199 Feb 20159 Ago 2016Nevro CorporationLinked area parameter adjustment for spinal cord stimulation and associated systems and methods
US9480842 *27 Oct 20141 Nov 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US959238822 Abr 201014 Mar 2017Nevro Corp.Devices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified contact selection
US959752121 Ene 201521 Mar 2017Bluewind Medical Ltd.Transmitting coils for neurostimulation
US960405919 Feb 201528 Mar 2017Nevro Corp.Devices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection
US971370712 Nov 201525 Jul 2017Bluewind Medical Ltd.Inhibition of implant migration
US976414621 Ene 201519 Sep 2017Bluewind Medical Ltd.Extracorporeal implant controllers
US978258910 Jun 201510 Oct 2017Bluewind Medical Ltd.Implantable electrostimulator for improving blood flow
US978259314 Jul 201610 Oct 2017Boston Scientific Neuromodulation CorporationFractionalized stimulation pulses in an implantable stimulator device
US20080154333 *10 Mar 200826 Jun 2008Venturi Group, LlcNeural blocking therapy
US20090192557 *22 Ene 200930 Jul 2009Whitehurst Todd KMethods and systems of treating pancreatitis pain caused by sphincter of oddi dysfunction
US20090192558 *22 Ene 200930 Jul 2009Whitehurst Todd KMethods and systems of treating pancreatitis pain
US20090204173 *4 Nov 200813 Ago 2009Zi-Ping FangMulti-Frequency Neural Treatments and Associated Systems and Methods
US20100152817 *20 May 200817 Jun 2010Ivor Stephen GillbeArray Stimulator
US20100191307 *29 Ene 200929 Jul 2010Zi-Ping FangSystems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US20100274312 *22 Abr 201028 Oct 2010Konstantinos AlatarisSpinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods
US20100274314 *22 Abr 201028 Oct 2010Konstantinos AlatarisSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20100274316 *22 Abr 201028 Oct 2010Konstantinos AlatarisDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified controllers
US20100274317 *22 Abr 201028 Oct 2010Jon ParkerDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified contact selection
US20100274318 *22 Abr 201028 Oct 2010Walker Andre BDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified program selection
US20110144716 *18 Sep 200816 Jun 2011Research Foundation Of The City University Of New YorkApparatus and Method for Neurocranial Electrostimulation
US20120203303 *13 Abr 20129 Ago 2012Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20130172955 *14 Sep 20124 Jul 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20130204322 *14 Mar 20138 Ago 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20130204323 *14 Mar 20138 Ago 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US20130204324 *14 Mar 20138 Ago 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US20130211487 *14 Sep 201215 Ago 2013Nevro CorporationMulti-frequency neural treatments and associated systems and methods
US20130261695 *14 Mar 20133 Oct 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US20130261696 *14 Mar 20133 Oct 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US20150045854 *27 Oct 201412 Feb 2015Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20150051664 *23 Oct 201419 Feb 2015Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20150142076 *27 Oct 201421 May 2015Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20160287872 *5 Abr 20166 Oct 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20160287873 *5 Abr 20166 Oct 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20160287874 *5 Abr 20166 Oct 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20160287875 *6 Abr 20166 Oct 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US20160287888 *5 Abr 20166 Oct 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20160303374 *20 Abr 201620 Oct 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
EP2207587B15 Nov 20088 Abr 2015Nevro CorporationMulti-frequency neural treatments and associated systems and methods
EP2586488B1 *21 Abr 201015 Mar 2017Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems
EP3097946A1 *22 Abr 201030 Nov 2016Nevro CorporationDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems
EP3228350A1 *21 Abr 201011 Oct 2017Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
WO2008142402A120 May 200827 Nov 2008Ivor Stephen GillbeArray stimulator
WO2009128810A1 *18 Sep 200822 Oct 2009Research Foundation Of The City University Of New YorkApparatus and method for neurocranial electrostimulation
WO2010088417A1 *28 Ene 20105 Ago 2010Nevro CorporationSystems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
Clasificaciones
Clasificación de EE.UU.607/45
Clasificación internacionalA61N1/00
Clasificación cooperativaA61N1/0551, A61N1/36071, A61N1/0531, A61N1/36064, A61N1/0534, A61N1/36067
Clasificación europeaA61N1/36Z, A61N1/36E, A61N1/36
Eventos legales
FechaCódigoEventoDescripción
27 Abr 2006ASAssignment
Owner name: VENTURI GROUP, LLC, MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KNUDSON, MARK B.;DONDERS, ADRIANUS P.;CONRAD, TIMOTHY R.;REEL/FRAME:017821/0549;SIGNING DATES FROM 20060323 TO 20060330
31 Ago 2017ASAssignment
Owner name: FLATHEAD PARTNERS, LLC, MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CONRAD, SARAH BRENZEL;DONDERS, ADRIANUS;NICKOLOFF, ANNE;AND OTHERS;SIGNING DATES FROM 20170718 TO 20170825;REEL/FRAME:043463/0302